Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4755207 | 0.90 | RECQL (0.64) | RECQLMEN1KMT2AALDH1A1 | |
| SCHEMBL4893109 | 0.89 | RECQL (0.55) | RECQLMEN1KMT2ATHRBSMN1; SMN2 | |
| SCHEMBL4752604 | 0.88 | RECQL (0.53) | RECQLMEN1KMT2ATHRBSMN1; SMN2 | |
| SCHEMBL14177949 | 0.85 | KDM4E (0.50) | ALDH1A1 | |
| SCHEMBL5121080 | 0.82 | KDM4E (0.47) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4788204 | 0.80 | RECQL (0.78) | RECQLMEN1KMT2ATHRBSMN1; SMN2 | |
| SCHEMBL4699355 | 0.79 | RECQL (0.63) | RECQLMEN1KMT2ATHRBSMN1; SMN2 | |
| SCHEMBL14177944 | 0.79 | PLA2G2A (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4753593 | 0.79 | RECQL (0.65) | RECQLMEN1KMT2AALDH1A1 | |
| SCHEMBL14177945 | 0.78 | MAPT (0.52) | RECQLSMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466681-A | Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2009-06-24 | — | — | CN | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | RECQL 3348/4885MEN1 1912/4885KMT2A 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.